AU2017258799A1 - Multiplexed optimized mismatch amplification (moma)-real time pcr for assessing cancer - Google Patents

Multiplexed optimized mismatch amplification (moma)-real time pcr for assessing cancer Download PDF

Info

Publication number
AU2017258799A1
AU2017258799A1 AU2017258799A AU2017258799A AU2017258799A1 AU 2017258799 A1 AU2017258799 A1 AU 2017258799A1 AU 2017258799 A AU2017258799 A AU 2017258799A AU 2017258799 A AU2017258799 A AU 2017258799A AU 2017258799 A1 AU2017258799 A1 AU 2017258799A1
Authority
AU
Australia
Prior art keywords
cancer
snv
nucleic acids
specific
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2017258799A
Other languages
English (en)
Inventor
Aoy Tomita Mitchell
Karl Stamm
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical College of Wisconsin
Original Assignee
Medical College of Wisconsin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical College of Wisconsin filed Critical Medical College of Wisconsin
Publication of AU2017258799A1 publication Critical patent/AU2017258799A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6858—Allele-specific amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2017258799A 2016-04-29 2017-04-29 Multiplexed optimized mismatch amplification (moma)-real time pcr for assessing cancer Abandoned AU2017258799A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662330043P 2016-04-29 2016-04-29
US62/330,043 2016-04-29
PCT/US2017/030291 WO2017190104A1 (en) 2016-04-29 2017-04-29 Multiplexed optimized mismatch amplification (moma)-real time pcr for assessing cancer

Publications (1)

Publication Number Publication Date
AU2017258799A1 true AU2017258799A1 (en) 2018-12-20

Family

ID=58709564

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017258799A Abandoned AU2017258799A1 (en) 2016-04-29 2017-04-29 Multiplexed optimized mismatch amplification (moma)-real time pcr for assessing cancer

Country Status (11)

Country Link
US (1) US20200181681A1 (cg-RX-API-DMAC7.html)
EP (1) EP3449014A1 (cg-RX-API-DMAC7.html)
JP (2) JP2019518437A (cg-RX-API-DMAC7.html)
CN (1) CN109715826A (cg-RX-API-DMAC7.html)
AU (1) AU2017258799A1 (cg-RX-API-DMAC7.html)
BR (1) BR112018072195A2 (cg-RX-API-DMAC7.html)
CA (1) CA3022545A1 (cg-RX-API-DMAC7.html)
EA (1) EA201892491A1 (cg-RX-API-DMAC7.html)
IL (1) IL262640A (cg-RX-API-DMAC7.html)
MX (1) MX2018013223A (cg-RX-API-DMAC7.html)
WO (1) WO2017190104A1 (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11111543B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US9424392B2 (en) 2005-11-26 2016-08-23 Natera, Inc. System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals
US11322224B2 (en) 2010-05-18 2022-05-03 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US12221653B2 (en) 2010-05-18 2025-02-11 Natera, Inc. Methods for simultaneous amplification of target loci
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci
US20190010543A1 (en) 2010-05-18 2019-01-10 Natera, Inc. Methods for simultaneous amplification of target loci
US12152275B2 (en) 2010-05-18 2024-11-26 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US12655483B2 (en) 2010-05-18 2026-06-16 Natera, Inc. Methods for simultaneous amplification of target loci
US10316362B2 (en) 2010-05-18 2019-06-11 Natera, Inc. Methods for simultaneous amplification of target loci
US9677118B2 (en) 2014-04-21 2017-06-13 Natera, Inc. Methods for simultaneous amplification of target loci
JP6153874B2 (ja) 2011-02-09 2017-06-28 ナテラ, インコーポレイテッド 非侵襲的出生前倍数性呼び出しのための方法
US20140100126A1 (en) 2012-08-17 2014-04-10 Natera, Inc. Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data
US20180173845A1 (en) 2014-06-05 2018-06-21 Natera, Inc. Systems and Methods for Detection of Aneuploidy
EP4428863A3 (en) 2015-05-11 2024-12-11 Natera, Inc. Methods and compositions for determining ploidy
JP7280044B2 (ja) 2016-04-15 2023-05-23 ナテラ, インコーポレイテッド 肺癌の検出方法
AU2017355458A1 (en) * 2016-11-02 2019-06-13 The Medical College Of Wisconsin, Inc. Methods for assessing risk using mismatch amplification and statistical methods
GB201618485D0 (en) 2016-11-02 2016-12-14 Ucl Business Plc Method of detecting tumour recurrence
CN110945136A (zh) 2017-06-20 2020-03-31 威斯康星州立大学医学院 使用总无细胞dna评估移植并发症风险
WO2019118926A1 (en) 2017-12-14 2019-06-20 Tai Diagnostics, Inc. Assessing graft suitability for transplantation
EP3737773B1 (en) 2018-01-12 2023-04-12 Natera, Inc. Novel primers and uses thereof
DK3781714T3 (da) 2018-04-14 2026-03-30 Natera Inc Fremgangsmåder til cancerpåvisning og -overvågning ved personlig påvisning af cirkulerende tumor-dna
US12234509B2 (en) 2018-07-03 2025-02-25 Natera, Inc. Methods for detection of donor-derived cell-free DNA
US11931674B2 (en) 2019-04-04 2024-03-19 Natera, Inc. Materials and methods for processing blood samples
WO2026096832A2 (en) * 2024-10-31 2026-05-07 Foundation Medicine, Inc. Determining significant copy number variants

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6034065A (en) 1992-12-03 2000-03-07 Arizona Board Of Regents Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10
CA2282504A1 (en) 1997-02-25 1998-08-27 Jun-Ping Xu Isolation and structural elucidation of the cytostatic linear and cyclo-depsipeptides dolastatin 16, dolastatin 17, and dolastatin 18
US20030148301A1 (en) * 1999-12-10 2003-08-07 Toshiya Aono Method of detecting nucleotide polymorphism
JP4116856B2 (ja) * 2002-10-02 2008-07-09 富士フイルム株式会社 1塩基多型の検出方法
CN102892901B (zh) * 2010-03-24 2015-11-25 凸版印刷株式会社 利用竞争性引物的目标碱基序列的检测方法
US10077474B2 (en) * 2012-05-29 2018-09-18 Abbott Molecular, Inc. Method of designing primers, method of detecting single nucleotide polymorphisms (SNPs), method of distinguishing SNPs, and related primers, detectable oligonucleotides, and kits
US20140242582A1 (en) 2013-02-28 2014-08-28 Ariosa Diagnostics, Inc. Detection of genetic abnormalities using ligation-based detection and digital pcr
HUE068191T2 (hu) * 2014-08-22 2024-12-28 Resolution Bioscience Inc A sejtmentes dns kvantitatív genetikai elemzésére szolgáló eljárások
AU2016255573A1 (en) * 2015-04-30 2017-12-21 The Medical College Of Wisconsin, Inc. Multiplexed optimized mismatch amplification (MOMA)-real time PCR for assessing cell-free DNA

Also Published As

Publication number Publication date
IL262640A (en) 2018-12-31
EA201892491A1 (ru) 2019-06-28
JP2019518437A (ja) 2019-07-04
US20200181681A1 (en) 2020-06-11
BR112018072195A2 (pt) 2019-02-12
MX2018013223A (es) 2019-04-22
EP3449014A1 (en) 2019-03-06
CA3022545A1 (en) 2017-11-02
WO2017190104A1 (en) 2017-11-02
CN109715826A (zh) 2019-05-03
JP2022084647A (ja) 2022-06-07

Similar Documents

Publication Publication Date Title
US20200181681A1 (en) Multiplexed optimized mismatch amplification (moma)-real time pcr for assessing cancer
US20210301320A1 (en) Multiplexed optimized mismatch amplification (moma)-cancer risk assessment with non-cancer associated targets
Mastoraki et al. ESR1 methylation: a liquid biopsy–based epigenetic assay for the follow-up of patients with metastatic breast cancer receiving endocrine treatment
US11279979B2 (en) Method of determining PIK3CA mutational status in a sample
Takai et al. Clinical utility of circulating tumor DNA for molecular assessment in pancreatic cancer
JP2022174081A (ja) ヘテロ接合性の消失(loss of heterozygosity)を評価するための方法および材料
Takai et al. Circulating tumor DNA as a liquid biopsy target for detection of pancreatic cancer
Hoshi et al. Rapid detection of epidermal growth factor receptor mutations in lung cancer by the SMart-Amplification Process
US20190153525A1 (en) Multiplexed optimized mismatch amplification (moma)-real time pcr for assessing fetal well being
AU2016306688A1 (en) Method of preparing cell free nucleic acid molecules by in situ amplification
KR102278401B1 (ko) 빈발 돌연변이의 신속도 및 민감도 검출 방법
KR20260066163A (ko) 조직 특이적 메틸화 마커
US20240279745A1 (en) Systems and methods for multi-analyte detection of cancer
US20220356533A1 (en) Biomarker composition for diagnosing or predicting prognosis of thyroid cancer, comprising preparation capable of detecting mutation in plekhs1 gene, and use thereof
US20250101494A1 (en) Methods for analyzing cytosine methylation and hydroxymethylation
US12391985B2 (en) Method of determining PIK3CA mutational status in a sample
US20240093302A1 (en) Non-invasive cancer detection based on dna methylation changes
Sun et al. A novel xenonucleic acid-mediated molecular clamping technology for early colorectal cancer screening
KR102416074B1 (ko) 생물학적 시료의 핵산 품질을 결정하는 방법
Chang et al. Detection of KRAS codon 12 and 13 mutations by mutant-enriched PCR assay
Saldivar et al. Analytic validation of NeXT Dx™, a comprehensive genomic profiling assay
US20260117308A1 (en) Systems and methods for multi-analyte detection of cancer
EP4624573A1 (en) Probe/primer library for cancer diagnosis
Prieto-Remon et al. Recent patents in circulating cell-free tumor DNA as biomarker in cancer
HK1238684B (en) Methods for rapid and sensitive detection of hotspot mutations

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ MULTIPLEXED OPTIMIZED MISMATCH AMPLIFICATION (MOMA)-REAL TIME PCR FOR ASSESSING CANCER

MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period